Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Virologic Outcomes of Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine.

NCT04880785 is registered in ClinicalTrials.gov with Fundacion SEIMC-GESIDA as lead sponsor.

NCT NCT04880785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04880785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Virologic Outcomes of Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine.
Lead sponsor
Fundacion SEIMC-GESIDA
Phase
Phase 2
Overall status
Completed
Start date
July 28, 2021
Completion date
April 9, 2024
Enrollment
167 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections